EMA Authorised: Deferiprone Lipomed (Deferiprone) — Lipomed GmbH

View source ↗

Summary

EMA authorised Deferiprone Lipomed for iron overload and beta-thalassemia with Lipomed GmbH as marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• Deferiprone Lipomed (Deferiprone)

Snippet

Status: Authorised. Therapeutic area: Iron Overload;beta-Thalassemia. MAH: Lipomed GmbH. Decision date: 26/06/2023